T 2307

Drug Profile

T 2307

Alternative Names: T-2307

Latest Information Update: 16 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Toyama Chemical
  • Class Antifungals; Benzamidines; Piperidines; Small molecules
  • Mechanism of Action Mitochondrial protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Mycoses
  • No development reported Aspergillosis; Candidiasis; Cryptococcosis

Most Recent Events

  • 15 Mar 2018 Phase I development is ongoing in USA (Toyama Chemical pipeline, March 2018)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mycoses in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Aspergillosis in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top